Atlas Trials

Pembrolizumab and Involved Site Radiation Therapy for Early Stage Relapsed or Primary Refractory Hodgkin Lymphoma

Clinical trial NCT03179917 · ACTIVE_NOT_RECRUITING

Trial details

NCT number
NCT03179917
Sponsor
Memorial Sloan Kettering Cancer Center
Status
ACTIVE_NOT_RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Hodgkin Lymphoma
Start date
2017-06-08
Primary completion
2026-06-15
Enrollment
22

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.